← Human Trials & Peer-Reviewed Studies
Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease
Plain-language guide to PMID 32113823 (2020): open-label randomized controlled trial study of Liraglutide, fatty liver & elevated liver enzymes.
Key Facts
- PMID
- 32113823
- Journal
- Clinics and research in hepatology and gastroenterology
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Zhang LY et al. (4 authors)
- DOI
- 10.1016/j.clinre.2020.01.007
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Liraglutide in the context of fatty liver & elevated liver enzymes.
Who Took Part
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
Sixty patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease were randomly assigned to the liraglutide and pioglitazone groups on a 1:1 basis using a computer-generated sequence.
How the Study Was Run
In design terms this was a randomized, open-label and parallel-group study.
The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.
Nothing was hidden in this open-label Liraglutide study: the participants and staff both knew the treatment.
Groups ran in parallel: each of the participants stayed in one arm throughout.
The methods mention a period of 24 weeks.
This was a single-center, open-label, prospective, and randomized trial using a parallel design and lasting 24 weeks.
Fetuin-A levels were determined using enzyme-linked immunosorbent assay.
Hepatic fat content was measured using proton 1H-MRS on a 1.5T whole-body MRI scanner.
All analyses were performed with SPSS version 13.0.
What Was Measured
PubMed files the paper under topics including Diabetes Mellitus, Type 2, Hypoglycemic Agents, Liraglutide, Non-alcoholic Fatty Liver Disease, Pioglitazone and alpha-2-HS-Glycoprotein.
The authors tagged it with the keywords Fetuin-A and Type 2 diabetes mellitus.
What This Means in Plain Language
The paper is a randomized, open-label and parallel-group study of Liraglutide in people with fatty liver & elevated liver enzymes over 24 weeks.
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2020 (Clinics and research in hepatology and gastroenterology), a journal based in France.
More context: the Liraglutide compound page, Fatty liver & elevated liver enzymes research.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.